← Back to blog
DividendOctober 7, 2026

Dividend Win Wednesday: The 3× Cash Cover Hiding Inside a 35% Chip Selloff

Top 5 Pixie Picks

Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Dividend stocks.

Sign in →

6. Biogen Inc. (BIIB)

Dividend yield: n/a | Payout ratio: 0% | 52w drawdown: -4%

FCF yield of 6.1% with zero dividend payout signals capital flexibility; the company sits 4% off its 52-week high while insider activity over six months shows ten transactions totaling three net shares purchased, all buys and zero sells. Gross margin of 76% and ROIC of 7% reflect the economics of a maturing biotech with stable franchises.

⬡ Litifilimab demonstrated rapid and durable efficacy in new 52-week Phase 2 data from the ongoing Phase 2/3 AMETHYST study, reinforcing its potential as a first-in-class therapy for cutaneous lupus erythematosus. The readout timing matters because lupus trial data loom ahead of the October 28 earnings call, which Jefferies expects to slightly beat on revenue.

Sean Godbout filed a Form 4 insider buy on October 5, the most recent executive transaction on the screen. The stock trades 4% below its high while insiders add at scale.

7. Cigna Group (CI)

Dividend yield: 2.3% | Payout ratio: 28% | 52w drawdown: -13%

Earnings yield of 42% at a P/E of 2.4 flags either an accounting anomaly or a market mispricing of normalized power; ten-year normalized earnings yield of 36.8% confirms the signal is structural, not transitory. FCF yield of 11.7% covers the dividend 5.1 times, the second-widest cover on the screen after Newmont.

Net debt-to-EBITDA of 1.72 and interest coverage of 6.5× are the weakest debt metrics in the top eight, though revenue growth of 11.7% year-over-year and ROIC of 11.2% suggest the leverage funds growth rather than distress.

Cigna Healthcare introduced Health Sense in early October to connect guidance, benefits, and clinical support around each person, improving affordability and outcomes. The product launch matters because managed care margins depend on utilization management, and this platform consolidates fragmented tools.

8. Nucor Corporation (NUE)

Dividend yield: 0.9% | Payout ratio: 29% | 52w drawdown: -10%

FCF yield of negative 0.3% is the only negative cash generation figure in the top eight, a red flag in a dividend screen where payout sustainability depends on free cash flow. Revenue growth of 5.7% and gross margin of 11.9% are the weakest profitability metrics on the list; the steel cycle is compressing margins faster than volume can offset.

Insider activity over six months shows 100% selling (185,808 net shares sold, zero buys), the largest absolute share count disposition on the screen. Cleveland-Cliffs jumped 10% as Stelco fallout faded before its October 19 earnings; Nucor and Steel Dynamics rose 5% in sympathy, though NUE insiders are exiting during the bounce.

Analyst consensus of $244 implies 3% downside from the current $252 price; the stock sits 10% off its high while negative FCF, insider selling, and weak margins converge. The setup here is a dividend that remains covered by net income but not by cash flow.


What to Watch

• October 22: Newmont earnings (est. EPS $1.93, revenue $6.3B). Management will frame the impact of higher gold prices and asset sales on 2027 FCF generation; the 6.6× payout cover suggests room for distribution increases if realized pricing holds.

• October 26–28: Semiconductor and biotech earnings cluster. Nucor reports October 26 (est. EPS $5.82); Novartis and KLA report October 27–28. The setup here is whether chip toolmakers guide to a 2027 recovery and whether Novartis frames the MS pipeline as a growth driver or a placeholder.

• October 28: Biogen earnings and lupus trial context. Jefferies expects a slight beat; the AMETHYST lupus data released in early October sets the bar for pipeline commentary.

• November 5: Energy and managed care earnings. ConocoPhillips, EOG, and Cigna all report; the setup here is whether the LNG deal ConocoPhillips signed translates to raised FCF guidance and whether Cigna's Health Sense launch shows up in utilization metrics.


Go Deeper

The dividend screener surfaces high-quality earners with durable payouts, low drawdowns, and strong free cash flow cover.

Check out the full screener →

Pro-only analytics

Named tickers from this article open in the app with Pro or an active trial.

Sign in →

Stock Pixie Pro

See the full dividend screen — every pick, every metric, every day.

The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.

Start your free trial →

Or start with the free Market Brief Digest

Where the market stands before the open, in plain language, every trading day. No account needed.

About the Stock Pixie Score

The Stock Pixie Score is a 0–10 composite that measures how well a stock matches the criteria for that screen. Scores reflect the strength of quantitative signals across valuation, quality, and trend factors weighted for the specific screener. A higher score means stronger alignment; above 8 indicates the algorithm finds the setup compelling across most of the metrics it tracks. It is a filter, not a forecast.

The Fine Print

Stock Pixie is not a registered investment adviser and does not offer financial advice. It is a stock screening platform that scores and ranks stocks using quantitative signals. You are responsible for your own research and investment decisions. Past performance does not guarantee future results.